Top Markets
Coin of the day
Frequency Therapeutics, Inc. Frequency Therapeutics, Inc.

Frequency Therapeutics, Inc.

FREQ
Kedudukan dalam Saham #32265
Frequency Therapeutics, Inc. is a clinical-stage biotechnology company... Frequency Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing treatments that unlock the body's inherent capacity for regeneration to restore impaired functions. Their "Progenitor Cell Activation" approach leverages small molecules to stimulate progenitor cells within the body, encouraging the formation of new, functional tissues. The company's flagship product candidate, FX-322, is currently in Phase IIa clinical trials, aiming to address the fundamental cause of sensorineural hearing loss. Beyond this, Frequency is also advancing therapies for various degenerative diseases, including multiple sclerosis, and ailments impacting muscles, the gastrointestinal system, skin, and bones. For the development and commercialization of FX-322, the company holds a license and collaboration agreement with Astellas Pharma Inc. Additionally, it maintains collaboration and licensing agreements with esteemed organizations such as Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. Founded in 2014, Frequency Therapeutics, Inc. is headquartered in Lexington, Massachusetts.
Harga Saham
$0.2996
Disegerakkan terakhir: 2023-11-03
Modal Pasaran
$10.58M
Perubahan (1 hari)
5.94%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Frequency Therapeutics, Inc. (FREQ)

Kategori

EPS untuk Frequency Therapeutics, Inc. (FREQ)
EPS setakat 2026 TTM: 0
Menurut laporan kewangan terkini dan harga saham Frequency Therapeutics, Inc., EPS semasa syarikat (TTM) adalah 0. Pada akhir tahun 2026, syarikat mempunyai EPS sebanyak 0 sama dengan EPS tahun 2026 iaitu 0.
Sejarah EPS untuk Frequency Therapeutics, Inc. dari 2026 hingga 2026
EPS pada akhir setiap tahun
Tahun EPS Ubah
Tidak cukup data untuk tarikh yang disediakan.
EPS untuk syarikat atau pesaing yang serupa